middle.news
Nyrada Completes Phase I Dosing of Xolatryp with No Safety Concerns
8:40am on Monday 21st of July, 2025 AEST
•
Biotechnology
Read Story
Nyrada Completes Phase I Dosing of Xolatryp with No Safety Concerns
8:40am on Monday 21st of July, 2025 AEST
Key Points
Final dosing and discharge of all six cohorts completed
No safety signals or dose-limiting toxicities observed
Comprehensive safety and pharmacokinetic data pending review
Preclinical studies show strong cardioprotective and neuroprotective effects
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NYRADA (ASX:NYR)
OPEN ARTICLE